Paraganglioma Market Trends and Investment Opportunities 2026-2030
Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Paraganglioma Market Report 2026" has been added to ResearchAndMarkets.com's offering.
The paraganglioma market is on an upward trajectory, with projections indicating a growth from $3.02 billion in 2025 to $3.76 billion by 2030, achieving a CAGR of 4.4%. This growth is propelled by advancements in biologic and immunotherapy drugs, a surge in autoimmune and infectious disorders, and innovative integrations like AI in diagnostics, teleophthalmology, and digital monitoring. These trends are reshaping the landscape of the paraganglioma market, enhancing diagnostic and treatment pathways.
Investment influx in oncology research is a key driver, addressing the global cancer burden with targeted and immunotherapy treatments. Significantly, spending on cancer medicines by IQVIA soared to $223 billion in 2023, with expectations to hit $409 billion by 2028. These investments support advancements in early diagnosis and improved treatment options for paraganglioma, fortifying clinical trials for more effective drug development.
Personalized medicine is a significant growth factor, tailoring treatments based on genetic markers. The use of genetic profiling in treatments enhances efficacy and minimizes side effects, vital for conditions linked to germline pathogenic variants in genes like SDHB and RET. In 2023, the FDA approved an increased number of personalized treatments, showcasing the impact of this evolving approach on the paraganglioma market.
Companies in the paraganglioma market, such as Merck & Co. Inc., are developing advanced therapies. For instance, the FDA's priority review of Welireg aims at providing targeted treatment for both pediatric and adult patients with advanced paraganglioma, illustrating the focus on innovative treatment developments.
Key players in the sector include F. Hoffmann-La Roche Ltd., Mount Sinai, and Stanford Health Care, among others, reflecting a robust competitive landscape. North America remains the market leader, while Asia-Pacific is poised as the fastest-growing region.
Report Scope
This report offers insights into market size, regional dynamics, and trends, providing stakeholders a strategic vantage point for engaging with the paraganglioma industry. The report underscores the pivotal role of early detection and personalized treatment solutions in managing this rare neuroendocrine tumor.
Reasons to Purchase:
Markets Covered: Types include Sympathetic and Parasympathetic Paragangliomas, among others. Origin, treatment types, distribution channels, and end-users are thoroughly examined. Subsegments dive into specific details like adrenal and extra-adrenal types.
Companies Mentioned: Key players include F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mount Sinai, Stanford Health Care, and others.
Geographical Scope: Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Regions: Asia-Pacific, South East Asia, Western and Eastern Europe, North and South America, Middle East, Africa.
Key Attributes
The companies featured in this Paraganglioma market report include:
For more information about this report visit https://www.researchandmarkets.com/r/bytb7z
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment